Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [18F]FMeNER-D2
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The in vivo binding of clinical dose of venlafaxine on norepinephrine transporter has been questioned because venlafaxine has higher in vitro affinity to serotonin transporter than that to norepinephrine transporter. Although serotonin transporter occupancy of clinically relevant doses of venlafaxine has been reported, there has been no report of norepinephrine transporter occupancy in the human brain. METHODS: This was an open-label, single center, exploratory positron emission tomography study. Twelve major depressive disorder patients who had responded to venlafaxine extended-release and 9 control subjects were recruited. Each subject participated in one positron emission tomography measurement with [18F]FMeNER-D2. Binding potential in brain was quantified by the area under the curve ratio method with thalamus as target and white matter as reference regions. The difference of binding potential values between control and patient groups divided to 2 dose ranges were evaluated. Norepinephrine transporter occupancy (%) for all the major depressive disorder patients was calculated using mean binding potential of control subjects as baseline. The relationships between dose or plasma concentration of total active moiety and occupancies of norepinephrine transporter were also estimated. RESULTS: The binding potential of the patient group with 150 to 300 mg/d was significantly lower than that in the control subjects group (P = .0004 < .05/2). The norepinephrine transporter occupancy (8-61%) increased in a dose-dependent manner although a clear difference beyond 150 mg/d was not observed. CONCLUSIONS: This study demonstrates that clinically relevant doses of venlafaxine extended-release block the norepinephrine transporter of the major depressive disorder patient's brain. The data support the notion that the antidepressant effect of venlafaxine involves a combination of serotonin transporter and norepinephrine transporter blockades.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, SNRIs inhibit the norepinephrine transporter (NET), which prevents the reuptake of NE into presynaptic neurons, leading to an increased concentration of NE in the synaptic cleft. 370”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [370]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Bymaster, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00298-6 · Cited by 717
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Reduced Levels of Norepinephrine Transporters in the Locus Coeruleus in Major Depression
Klimek, V., Stockmeier, C., Overholser, J., Meltzer, H. Y., Kalka, S., Dilley, G., & Ordway, G. A. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-21-08451.1997 · Cited by 445 · cited 1×
“Postmortem data, and recently also in vivo data, suggest changes in NET densities in MDD subjects (Klimek et al., 1997; Moriguchi et al., 2017b).”
BackgroundLocher, C., Koechlin, H., Zion, S. R., Werner, C., Pine, D. S., Kirsch, I., Kessler, R. C., & Kossowsky, J. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2432 · Cited by 360
Meyer, J. H., Wilson, A. A., Ginovart, N., Goulding, V., Hussey, D., Hood, K., & Houle, S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1843 · Cited by 340
Nelson, J. C. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810280019002 · Cited by 294
Papakostas, G. I., Fava, M., & Thase, M. E. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.08.010 · Cited by 284
Meta-analysis of molecular imaging of serotonin transporters in major depression
Gryglewski, G., Lanzenberger, R., Kranz, G. S., & Cumming, P. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.82 · Cited by 227 · cited 1×
“, the serotonin transporter (5-HTT) (Savitz and Drevets, 2013; Gryglewski et al., 2014).”
Varrone, A., Sjöholm, N., Eriksson, L., Gulyás, B., Halldin, C., & Farde, L. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1156-3 · Cited by 206 · cited 1×
“The data were reconstructed using the ordinary Poisson-3D-ordered subset expectation maximization (OP-3D-OSEM) algorithm with 10 iterations and 16 subsets including modeling of the point spread function (Varrone et al., 2009).”
MethodSelf-citationJakubovski, E., Varigonda, A. L., Freemantle, N., Taylor, M. J., & Bloch, M. H. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15030331 · Cited by 197 · cited 1×
“In line with this observation, drugs that inhibit the reuptake of 5-HT such as selective serotonin reuptake inhibitors (SSRIs) have repeatedly proven efficacious for the treatment of MDD in many but not all subjects (Jakubovski et al., 2016; Locher et al., 2017; Cipriani et al., 2018).”
BackgroundNelson, J. C., Mazure, C. M., Jatlow, P. I., Bowers, M. B., & Price, L. H. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.08.007 · Cited by 189
Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity
Vaishnavi, S. N., Nemeroff, C. B., Plott, S. J., Rao, S. G., Kranzler, J., & Owens, M. J. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.07.006 · Cited by 178
Neuroreceptor imaging in depression
Savitz, J. B., & Drevets, W. C. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.06.001 · Cited by 165 · cited 1×
“, the serotonin transporter (5-HTT) (Savitz and Drevets, 2013; Gryglewski et al., 2014).”
Rudolph, R. L., Fabre, L. F., Feighner, J. P., Rickels, K., Entsuah, R., & Derivan, A. T. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0305 · Cited by 132
Schou, M., Halldin, C., Sóvágó, J., Pike, V. W., Hall, H., Gulyás, B., Mozley, P. D., Dobson, D., Shchukin, E., Innis, R. B., et al. (2004) · Synapse · doi:10.1002/syn.20031 · Cited by 129
Self-citationSuhara, T., Takano, A., Sudo, Y., Ichimiya, T., Inoue, M., Yasuno, F., Ikoma, Y., & Okubo, Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.4.386 · Cited by 126 · cited 1×
“The 5-HTT occupancy has been highlighted as a measure of antidepressant treatment effect (Meyer et al., 2001, 2004; Suhara et al., 2003; Lundberg et al., 2012).”
BackgroundSelf-citationKoch, S., Hemrick-Luecke, S. K., Thompson, L., Evans, D. C., Threlkeld, P. G., Nelson, D. L., Perry, K. W., & Bymaster, F. P. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00268-5 · Cited by 117
A dose-finding study of duloxetine based on serotonin transporter occupancy
Takano, A., Suzuki, K., Kosaka, J., Ota, M., Nozaki, S., Ikoma, Y., Tanada, S., & Suhara, T. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0304-0 · Cited by 110
Self-citationVoineskos, A. N., Wilson, A. A., Boovariwala, A., Sagrati, S., Houle, S., Rusjan, P., Sokolov, S. T. H., Spencer, E. P., Ginovart, N., & Meyer, J. H. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0806-z · Cited by 81
Norepinephrine Transporter in Major Depressive Disorder: A PET Study
Moriguchi, S., Yamada, M., Takano, H., Nagashima, T., Takahata, K., Yokokawa, K., Ito, T., Ishii, T., Kimura, Y., Zhang, M.-R., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.15101334 · Cited by 72
Regulation of the norepinephrine transporter by chronic administration of antidepressants
Benmansour, S., Altamirano, A. V., Jones, D. J., Sanchez, T. A., Gould, G. G., Pardon, M., Morilak, D. A., & Frazer, A. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00676-0 · Cited by 68
Owens, M. J., Krulewicz, S., Simon, J. S., Sheehan, D. V., Thase, M. E., Carpenter, D. J., Plott, S. J., & Nemeroff, C. B. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.47 · Cited by 68
Bauer, M. E., & Tejani-Butt, S. M. (1992) · Brain Research · doi:10.1016/0006-8993(92)90134-u · Cited by 64
Hébert, C., Habimana, A., Elie, R., & Reader, T. A. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(00)00043-7 · Cited by 63
Thase, M. E., Shelton, R. C., & Khan, A. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000219922.19305.08 · Cited by 59 · cited 1×
“The question whether the reported higher response rate in doses of 225 or 375 mg/d (Rudolph et al., 1998; Thase et al., 2006) may be explained by even higher NET occupancy than at 150 mg/d should be addressed in a PET study designed and powered for this specific purpose.”
BackgroundGallezot, J.-D., Weinzimmer, D., Nabulsi, N., Lin, S.-F., Fowles, K., Sandiego, C., McCarthy, T. J., Maguire, R. P., Carson, R. E., & Ding, Y.-S. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.09.040 · Cited by 59
Regulation of norepinephrine transporter abundance by catecholamines and desipramine in vivo
Weinshenker, D., White, S. S., Javors, M. A., Palmiter, R. D., & Szot, P. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02889-5 · Cited by 52
Arakawa, R., Okumura, M., Ito, H., Seki, C., Takahashi, H., Takano, H., Nakao, R., Suzuki, K., Okubo, Y., Halldin, C., et al. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.051292 · Cited by 50 · cited 5×
“A method for reliable quantification of [(18)F]FMeNER-D2 binding to NET in human in vivo using PET has been described (Arakawa et al., 2008).”
MethodInfluentialSelf-citationCharlier, C., Pinto, E., Ansseau, M., & Plomteux, G. J. (2002) · Journal of Psychopharmacology · doi:10.1177/026988110201600413 · Cited by 50
Moriguchi, S., Takano, H., Kimura, Y., Nagashima, T., Takahata, K., Kubota, M., Kitamura, S., Ishii, T., Ichise, M., Zhang, M.-R., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx069 · Cited by 47
Perahia, D. G. S., Quail, D., Desaiah, D., Corruble, E., & Fava, M. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0113 · Cited by 46 · cited 1×
“Also, MDD patients who failed to respond to SSRIs have been shown to improve when switched to serotonin and norepinephrine reuptake inhibitors (SNRIs), which have dual-target sites including 5-HTT and NET (Papakostas et al., 2008; Perahia et al., 2008).”
BackgroundNogami, T., Takano, H., Arakawa, R., Ichimiya, T., Fujiwara, H., Kimura, Y., Kodaka, F., Sasaki, T., Takahata, K., Suzuki, M., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001009 · Cited by 46
Self-citationLundberg, J., Tiger, M., Landén, M., Halldin, C., & Farde, L. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001945 · Cited by 46
Self-citationChen, X., Kudo, T., Lapa, C., Buck, A. K., & Higuchi, T. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02180-4 · Cited by 44
Sekine, M., Arakawa, R., Ito, H., Okumura, M., Sasaki, T., Takahashi, H., Takano, H., Okubo, Y., Halldin, C., & Suhara, T. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1824-9 · Cited by 39 · cited 1×
“The applicability of [18F] FMeNER-D2 PET in clinical occupancy studies have been shown in several reports (Sekine et al., 2010; Nogami et al., 2013; Nyberg et al., 2013; Takano et al., 2014; Moriguchi et al., 2017a).”
BackgroundSelf-citationNorepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR
Nyberg, S., Jucaite, A., Takano, A., Kågedal, M., Cselényi, Z., Halldin, C., & Farde, L. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000680 · Cited by 38
Self-citationTakano, H., Arakawa, R., Nogami, T., Suzuki, M., Nagashima, T., Fujiwara, H., Kimura, Y., Kodaka, F., Takahata, K., Shimada, H., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001521 · Cited by 34
Self-citationMapping of the norepinephrine transporter in the human brain using PET with (S,S)-[18F]FMeNER-D2
Takano, A., Varrone, A., Gulyás, B. Z., Karlsson, P., Tauscher, J. T., & Halldin, C. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.05.040 · Cited by 32 · cited 5×
“Previous PET studies using reference tissue models to quantify [(18)F]FMeNER-D2 binding have applied either caudate (Arakawa et al., 2008; Takano et al., 2008) or white matter (Takano et al.”
BackgroundMethodInfluentialSelf-citationEffect of Terbinafine and Voriconazole on the Pharmacokinetics of the Antidepressant Venlafaxine
Hynninen, V.-V., Olkkola, K. T., Bertilsson, L., Kurkinen, K. J., Neuvonen, P. J., & Laine, K. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100311 · Cited by 30
SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study
Takano, A., Halldin, C., & Farde, L. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2901-z · Cited by 29 · cited 2×
“In a previous nonhuman primate (NHP) PET study, similar in vivo occupancy between 5-HTT and NET of venlafaxine has been demonstrated (Takano et al., 2013).”
BackgroundMethodSelf-citationTakano, A., Gulyás, B. Z., Varrone, A., Maguire, R. P., & Halldin, C. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1118-9 · Cited by 28
Self-citationThase, M. E., Asami, Y., Wajsbrot, D., Dorries, K. M., Boucher, M., & Pappadopulos, E. A. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1255185 · Cited by 19 · cited 1×
“Venlafaxine, which was clinically introduced as the first SNRI for the treatment of MDD in 1993, has been widely and globally prescribed and its major prescribed formulation is the extended release (ER) (Thase et al., 2017).”
BackgroundSelf-citationLinden, M., Ludewig, K., Munz, T., & Dierkes, W. (2003) · Pharmacopsychiatry · doi:10.1055/s-2003-43050 · Cited by 12
Schoretsanitis, G., Haen, E., Gründer, G., Hiemke, C., Endres, K., Ridders, F., Correll, C. U., & Paulzen, M. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02675-4 · Cited by 10
Cited by
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
“370 Second, similar to SSRIs, SNRIs also inhibit SERT, resulting in an increased concentration of 5-HT in the synaptic cleft.”
BackgroundAntidepressant Drugs Effects on Blood Pressure
Calvi, A., Fischetti, I., Verzicco, I., Murri, M. B., Zanetidou, S., Volpi, R., Coghi, P., Tedeschi, S., Amore, M., & Cabassi, A. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.704281 · Cited by 175
“At lower doses, the inhibition of 5-HT reuptake prevails, whereas at high doses (over 225mg) venlafaxine mainly acts as a NE reuptake inhibitor (100, 101).”
BackgroundBehlke, L. M., Lenze, E. J., & Carney, R. M. (2020) · CNS Drugs · doi:10.1007/s40263-020-00763-z · Cited by 135
Neuroinflammation and Natural Antidepressants: Balancing Fire with Flora
Figueiredo Godoy, A. C., Frota, F. F., Araújo, L. P., Valenti, V. E., Pereira, E. D. S. B. M., Detregiachi, C. R. P., Galhardi, C. M., Caracio, F. C., Haber, R. S. A., Fornari Laurindo, L., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13051129 · Cited by 32
“However, alternative classes such as serotonin–norepinephrine reuptake inhibitors (SNRIs), TCAs, monoamine oxidase inhibitors (MAOIs), and N-methyl-D-aspartate (NMDA) antagonists provide additional therapeutic pathways, especially in treatment-Biomedicines resistant cases [10,200–202].”
Chen, X., Kudo, T., Lapa, C., Buck, A. K., & Higuchi, T. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02180-4 · Cited by 44
Metadata
- Authors
- Arakawa, R., Stenkrona, P., Takano, A., Svensson, J., Andersson, M., Nag, S., Asami, Y., Hirano, Y., Halldin, C., & Lundberg, J.
- Affiliations
- Region Stockholm (SE)
- Pfizer (Japan) (JP)
- Corresponding author
- Arakawa, Ryosuke
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-01-11
- Volume
- 22
- Issue
- 4
- Pages
- 278-285
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC6441126
- OpenAlex
- W2910200143
- Cited by
- 70
- References
- 46
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 9 · 2023: 3 · 2022: 8 · 2021: 27 · 2020: 8 · 2019: 1
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Swedish Research Council
- Pfizer Japan Inc.
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- venlafaxine extended release, norepinephrine transporter, major depressive disorder, binding potential, serotonin transporter, antidepressant mechanism, dose-dependent binding
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Venlafaxine Hydrochloride, Adult, Aged, Brain, Delayed-Action Preparations, Major Depressive Disorder, Female, Humans, Male, Middle Aged, Morpholines, Positron-Emission Tomography, Norepinephrine Plasma Membrane Transport Proteins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.